ALPN Stock Cash Flow Statements

Alpine Immune Sciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Alpine Immune Sciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30

operating activities
net income	-17,918,000	5,960,000	-11,722,000	-13,156,000	-13,266,000	-18,864,000	-13,273,000	-18,098,000	-7,527,000	-15,167,000	-13,494,000	-11,029,000	-10,643,000	-6,342,000	-6,137,000	-9,928,000	-5,533,000	-6,140,000	-11,475,000	-11,856,000	-12,381,000	-11,135,000	-12,139,000	-7,907,000	-5,306,000	-4,318,000	9,161,000		-7,433,000	-8,479,000	-7,838,000	-6,563,000	-6,089,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	3,989,000	2,803,000	2,654,000	2,621,000	2,552,000	2,469,000	2,555,000	2,335,000	2,289,000	1,460,000	1,638,000	1,545,000	1,597,000	949,000	973,000	1,232,000	986,000	780,000											852,000	700,000	707,000	625,000	348,000
amortization of premium/discount on investments	-2,734,000	-2,561,000	-2,093,000	-1,674,000	-1,723,000	-1,334,000	43,000	259,000	332,000	304,000	192,000	192,000	218,000	163,000	-2,000	-17,000	-41,000	-86,000	-89,000	-53,000	-132,000	-216,000	-85,000
depreciation expense	147,000	148,000	146,000	142,000	140,000	145,000	148,000	156,000	148,000	138,000	155,000	162,000	165,000	159,000	140,000	144,000	135,000	124,000	115,000	-76,000	305,000	109,000	109,000	90,000	80,000
non-cash interest expense and other
realized gain on investments	-18,000	0	0
changes in operating assets and liabilities:
accounts receivable	123,000	57,000	62,000	383,000	-277,000	-16,000	935,000	-1,185,000	24,868,000
prepaid expenses and other current assets	-405,000	1,180,000	-465,000	228,000	-90,000	1,143,000	-790,000	1,035,000	613,000	-1,563,000	596,000	98,000	-2,194,000	-17,000	-360,000	1,255,000	-623,000	4,084,000	-4,077,000	-718,000	303,000	-144,000	752,000
operating lease, right-of-use asset	193,000	187,000	180,000	174,000	168,000	162,000	158,000
accounts payable and accrued liabilities	-3,818,000	4,029,000	5,490,000	1,745,000	-4,745,000	1,980,000	2,019,000	3,409,000	-1,851,000	1,837,000	4,485,000	1,603,000	-1,955,000	785,000	1,191,000	1,538,000	-4,005,000	-4,780,000	3,767,000
deferred revenue	-6,990,000	-30,687,000	-9,823,000	-8,310,000	-8,719,000	-2,257,000	-7,987,000	-4,106,000	-13,497,000	-1,458,000	36,483,000	-7,194,000	-3,203,000	-5,518,000	-1,663,000	59,812,000	-1,091,000	-634,000	-39,000			-1,000	0	-240,000	-239,000	-128,000
operating lease liability	-259,000	-242,000	-236,000	-230,000	-220,000	-205,000	-200,000
net cash from operating activities	-27,690,000	-18,971,000	-15,798,000	-18,091,000	-26,152,000	-16,786,000	-16,348,000	-16,069,000	5,449,000	-14,729,000	30,134,000	-14,682,000	-15,971,000	-9,349,000	-5,392,000	54,519,000	-9,694,000	-5,671,000	-10,575,000	-7,877,000	-11,223,000	-9,398,000	-7,372,000	-7,215,000	-4,431,000	-5,837,000	891,000	-5,177,000	-7,524,000	-6,547,000	-7,011,000	-5,401,000	-5,726,000
capex	-19,000	-114,000	-1,000	-279,000	-93,000	-116,000	-55,000	-215,000	-26,000	-49,000	0	-30,000	-39,000	-488,000	-60,000	-198,000	-56,000	-486,000	-135,000	-79,000	-121,000	-9,000	-208,000	-160,000	-118,000	0	0	0	-16,000	-43,000	-31,000	-46,000	-55,000
free cash flows	-27,709,000	-19,085,000	-15,799,000	-18,370,000	-26,245,000	-16,902,000	-16,403,000	-16,284,000	5,423,000	-14,778,000	30,134,000	-14,712,000	-16,010,000	-9,837,000	-5,452,000	54,321,000	-9,750,000	-6,157,000	-10,710,000	-7,956,000	-11,344,000	-9,407,000	-7,580,000	-7,375,000	-4,549,000	-5,837,000	891,000	-5,177,000	-7,540,000	-6,590,000	-7,042,000	-5,447,000	-5,781,000
investing activities
purchase of investments	-75,393,000	-162,088,000	-85,538,000	-69,368,000	-34,353,000	-146,649,000	-37,955,000	-36,103,000	-46,277,000	-33,561,000	-84,446,000	-5,604,000	-9,907,000
maturities of investments	72,850,000	49,500,000	85,004,000	98,975,000	62,796,000	38,866,000	63,800,000	42,882,000	8,500,000	29,325,000	21,931,000	26,500,000	3,400,000
purchases of property and equipment	-19,000	-114,000	-1,000	-279,000	-93,000	-116,000	-55,000	-215,000	-26,000	-49,000	0	-30,000	-39,000	-488,000	-60,000	-198,000	-56,000	-486,000	-135,000	-79,000	-121,000	-9,000	-208,000	-160,000	-118,000				-16,000	-43,000	-31,000	-46,000	-55,000
net cash from investing activities	-2,562,000	-112,702,000	-535,000	29,328,000	28,350,000	-107,899,000	25,790,000	6,564,000	-37,803,000	-4,285,000	-62,515,000	20,866,000	-6,546,000	-96,849,000	1,843,000	9,057,000	13,130,000	4,388,000	10,863,000	-17,587,000	19,099,000	9,136,000	15,774,000	3,338,000	3,870,000	1,855,000	-46,629,000	13,149,000	8,265,000	5,841,000	-1,950,000	-27,225,000	-35,136,000
financing activities
adjustments to offering costs	-8,000
repayment of debt		0	0	-2,225,000	-1,200,000	-1,200,000	-1,200,000	-1,200,000	-1,200,000	-1,200,000								0	-333,000	-500,000	-500,000	-500,000
proceeds from exercise of stock options, net of taxes paid on vested rsus	1,780,000
proceeds from exercise of warrants	17,579,000
net cash from financing activities	19,351,000	156,610,000	1,201,000	8,398,000	-1,087,000	11,543,000	92,816,000	-1,020,000	-650,000	10,873,000	89,680,000	9,000	202,000	-11,000	56,390,000	2,000	5,000,000	0	1,646,000	-509,000	23,118,000	-500,000	-498,000	0	7,000	0		63,000	11,000			62,000	-2,104,000
effect of exchange rate on cash and cash equivalents	-4,000	17,000	37,000	-24,000	-22,000	-107,000	7,000
net increase in cash and cash equivalents and restricted cash	-10,905,000	24,954,000	-15,095,000	19,611,000	1,089,000	-113,249,000				-8,192,000	57,286,000	6,184,000	-22,330,000	-106,116,000	52,855,000	63,642,000	8,323,000	-1,272,000	1,927,000	-25,969,000	30,980,000	-762,000	7,904,000	-3,877,000	-554,000	-3,982,000
cash and cash equivalents and restricted cash, beginning of period	44,189,000	0	0	0	13,630,000	0	0	0	68,161,000	0	0	0	35,213,000	0	0	0	16,509,000	0	0	0	10,843,000	0	0	0	8,132,000
cash and cash equivalents and restricted cash, end of period	33,284,000	24,954,000	-15,095,000	19,611,000	14,719,000	-113,249,000	102,265,000	-10,529,000	35,143,000	-8,192,000	57,286,000	6,184,000	12,883,000	-106,116,000	52,855,000	63,642,000	24,832,000	-1,272,000	1,927,000	-25,969,000	41,823,000	-762,000	7,904,000	-3,877,000	7,578,000
supplemental information
cash paid for interest					47,000	60,000	70,000	88,000	104,000	122,000	141,000	147,000	144,000	145,000	147,000	125,000	73,000	73,000	30,000	32,000	35,000	38,000	39,000	38,000	34,000
non-cash interest expense		0	0	19,000	26,000	33,000	40,000	49,000	56,000	61,000	67,000	74,000	72,000	69,000	67,000	81,000	44,000	41,000	32,000	32,000	35,000	38,000	43,000	44,000	44,000	44,000
loss on sale of property and equipment		0	9,000	0	2,000	25,000	-2,000	13,000	57,000
deferred income tax						-67,000	6,000			-153,000												0	0	-253,000	-52,000
proceeds from sale of common stock and warrants, net of offering costs						12,712,000				-79,000				-13,000
proceeds from issuance of common stock to amgen
cash paid for income taxes
proceeds from sale of common stock, net of offering costs			-1,000															0	0	-20,000	23,618,000
proceeds from exercise of stock options			1,202,000	928,000	113,000	31,000	12,000	180,000	550,000	223,000	68,000	9,000	202,000	2,000	119,000			0	2,000
proceeds from issuance of common stock to horizon
proceeds from borrowings, net of issuance costs														0	0	0	5,000,000	0
discount in connection with issuance of debt														-1,000	0	0	335,000									0
net decrease in cash and cash equivalents and restricted cash								-10,529,000	-33,018,000
right-of-use asset									146,000	143,000	138,000	133,000	150,000	134,000	140,000	171,000	147,000
lease liabilities									-185,000	-335,000	-167,000	-164,000	-178,000	264,000	259,000	231,000	287,000	70,000	121,000
effect of exchange rate on cash, cash equivalents and restricted cash									-14,000	-51,000	-13,000	-9,000	-15,000	93,000	14,000	64,000	-113,000
proceeds from the sale of investments
recognition of right-of-use asset																		-494,000	-90,000	10,874,000	883,000
deferred tax asset
gain on sale of property and equipment
loss on sale of intangible asset																						0	0
proceeds from sale of intangible asset																						0	0
purchase of short-term investments															-96,000	43,000	-4,914,000	-5,076,000	-14,502,000	-26,508,000	-13,296,000	-9,655,000	-21,818,000	-4,353,000	-37,037,000	-16,068,000
maturities of short-term investments															1,999,000	9,212,000	18,100,000	9,950,000	25,500,000	9,000,000	31,125,000	18,800,000	37,800,000
proceeds from the sale of short-term investments																		0	0	0	1,391,000				41,025,000
bargain purchase gain																										-62,000
cash and cash equivalents acquired in connection with merger																										0
proceeds from sale of preferred stock																										0
convertible preferred stock exchanged for common stock																										0
amortization of right-of-use asset																			245,000
deferred rent and other																					-213,000	-19,000	-15,000	-13,000	19,000	-11,000
effect of exchange rate changes on cash, cash equivalents and restricted cash																			-7,000	4,000	-14,000
stock-based compensation and warrant expense																				682,000	754,000	731,000	544,000	523,000	511,000
accounts payable																					-973,000	1,276,000	-310,000	222,000	335,000	-858,000	2,030,000		-1,098,000	914,000	202,000	-558,000	204,000
accrued liabilities																					1,079,000	-37,000	3,729,000	-1,000	204,000	-341,000
proceeds from borrowings																										0
proceeds from exercise of stock options and common stock warrants																						0	2,000	0	7,000	0
reclass of preferred stock warrant liability to equity																										0
prepaid expenses																									-27,000	-345,000
operating activities:
common stock issued for intellectual property
investing activities:
purchase of property and equipment
proceeds from sale short-term investments
financing activities:
cash and cash equivalents and restricted cash at beginning of period
cash and cash equivalents and restricted cash at end of period
depreciation and amortization
depreciation																													38,000	36,000	30,000		16,000
gain on sales of property and equipment
prepaid expenses and other																													-346,000	-99,000	-69,000	564,000	-427,000
accrued direct program expenses																													95,000	133,000	1,054,000	98,000	-225,000
accrued restructuring charges
accrued employee benefits																													360,000	273,000	-963,000	339,000	359,000
accrued other liabilities																													8,000	-25,000	-134,000	75,000
proceeds from sales of property and equipment
purchases of marketable securities																													-13,919,000	-22,766,000	-29,469,000	-41,179,000
proceeds from sales and maturities of marketable securities																													22,200,000	28,650,000	27,550,000
proceeds from employee stock purchases and stock options exercised																													11,000
net increase in cash and cash equivalents																												8,035,000	752,000			-32,564,000	-42,966,000
cash and cash equivalents, beginning of period																													0	0	24,991,000	0	0
cash and cash equivalents, end of period																													752,000	-614,000	16,030,000	-32,564,000	-42,966,000
proceeds from issuance of common stock, net of offering costs																																-1,000	-2,104,000
supplemental disclosures of cash flow information
conversion of convertible preferred stock to common stock																																0	0
net decrease in cash and cash equivalents																															-8,961,000
description																															2,016,000
assets measured at fair value:
money market investments																															7,592,000
u.s. treasury securities, obligations of u.s. government agencies, corporate debt securities and reverse repurchase agreements																															70,182,000
depreciation and loss on disposal of assets
change in value of preferred stock warrant liabilities and derivative
amortization of deferred financing costs and noncash interest
proceeds from issuance of convertible preferred stock
decrease in restricted cash
proceeds from notes payable
principal payment on debt
conversion of convertible debt and accrued interest to convertible preferred stock
loss on disposal of assets

We provide you with 20 years of cash flow statements for Alpine Immune Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Alpine Immune Sciences stock. Explore the full financial landscape of Alpine Immune Sciences stock with our expertly curated income statements.

The information provided in this report about Alpine Immune Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.